The commercial pharmaceutical market of the 1990s has all but disappeared: Low-priced drugs designed to treat large-market diseases like depression and high cholesterol are making way for higher-priced specialty drugs designed to treat small, targeted patient populations. With this shift, emerging biopharmaceutical companies are not only developing an increasing number of novel drugs, but increasingly launching those assets.We see three major trends taking shape as more emerging biopharma companies prepare to launch: an increase in the number of originator products and US approval filings, an uptick in expedited approvals and self-commercialization, and greater presence in markets outside the US.

 

In our recent article for PharmExec, we share a look ahead at these market-shaping launch trends, and what’s needed to build a strong capability and ensure longevity in this segment of the industry.